F1000Research · 2018 · 55 citations · 23 references
PharmacyPharmaceutical PolicyPharmacoeconomicsDrug Approval ProcessesEvidence-based PracticeGood Clinical PracticeClinical TrialsDrug EvaluationEvidence-based MedicineNew Drug ApplicationsReal-world EvidenceTranslating Evidence Into PracticeEvidence-based InnovationLifecycle Evidence GenerationProduct Lifecycle AnalysisReal-world Evidence AppraisalReal-world Evidence AssessmentReal-world Evidence EvaluationReal-world Evidence SourcesTreatment Effectiveness Analysis
<ns4:p>Stakeholders in healthcare are increasingly turning to real world evidence (RWE) to inform their decisions, alongside evidence from randomized controlled trials. RWE is generated by analysing data gathered from routine clinical practice, and can be used across the product lifecycle, providing insights into areas including disease epidemiology, treatment effectiveness and safety, and health economic value and impact. Recently, the US Food and Drug Administration and the European Medicines Agency have stated their ambition for greater use of RWE to support applications for new indications, and are now consulting with their stakeholders to formalize standards and expected methods for generating RWE.</ns4:p> <ns4:p>Pharmaceutical companies are responding to the increasing demands for RWE by developing standards and processes for each stage of the evidence generation pathway. Some conventions are already in place for assuring quality, whereas other processes are specific to the research question and data sources available. As evidence generation increasingly becomes a core role of medical affairs divisions in large pharmaceutical companies, standards of rigour will continue to evolve and improve. Senior pharmaceutical leaders can drive this change by making RWE a core element of their corporate strategy, providing top-level direction on how their respective companies should approach RWE for maximum quality.</ns4:p> <ns4:p>Here, we describe the current and future areas of RWE application within the pharmaceutical industry, necessary access to data to generate RWE, and the challenges in communicating RWE. Supporting and building on viewpoints from industry and publicly funded research, our perspective is that at each stage of RWE generation, quality will be critical to the impact that RWE has on healthcare decision-makers; not only where RWE is an established and evolving tool, but also in new areas that have the potential to disrupt and to improve drug development pathways.</ns4:p>
23
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · PLoS Medicine · 2007 · 21.6K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
The FAIR Guiding Principles for scientific data management and stewardship
Mark D. Wilkinson, Michel Dumontier, IJsbrand Jan Aalbersberg et al. · Scientific Data · 2016 · 17.8K citations · Full text
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · Journal of Clinical Epidemiology · 2008 · 16.4K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon, Shaun Treweek, Frank Sullivan et al. · BMJ · 2015 · 1.8K citations · Full text